Biomet (NASDAQ:BMET)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Biomet Charts. Click Here for more Biomet Charts.](/p.php?pid=staticchart&s=N%5EBMET&p=8&t=15)
Biomet, Inc. (NASDAQ:BMET) today announced that Charles
E. Niemier has been appointed as President of EBI's operations
following the resignation of Bart J. Doedens, M.D., former President
of EBI, who has decided to pursue other interests. Mr. Niemier has
been a member of senior management and the Board of Directors of
Biomet for more than 25 years and has served in a variety of
operational roles with Biomet during his tenure including Chief
Financial Officer and, more recently, Chief Operating Officer -
International Operations. Additionally, Robert Phelps has been
promoted to Vice President-Sales at EBI. Mr. Phelps has over 25 years
of experience in the orthopedic industry with Johnson & Johnson and
most recently with Biomet as its Area Vice President,
Northeast/Mid-Atlantic Sales. Joe Milano has joined EBI as its Vice
President, Finance and Administration. Mr. Milano was most recently
Executive Vice President and CFO for Aircast.
Biomet's Interim President and Chief Executive Officer, Daniel P.
Hann, commented, "We are pleased to announce the appointment of Mr.
Niemier as President of EBI. We are confident that Mr. Niemier will
provide the leadership capabilities necessary to position EBI as a
leader in the spinal and fixation market places, and improve our
leadership position in electrical stimulation. Additionally, the
senior management team at EBI has been significantly strengthened with
the additions of both Mr. Phelps and Mr. Milano in the key areas of
sales management and finance."
Biomet, Inc. and its subsidiaries design, manufacture and market
products used primarily by musculoskeletal medical specialists in both
surgical and non-surgical therapy. The Company's product portfolio
encompasses reconstructive products, including orthopedic joint
replacement devices, bone cements and accessories, and dental
reconstructive implants; fixation products, including electrical bone
growth stimulators, internal and external orthopedic fixation devices,
craniomaxillofacial implants and bone substitute materials; spinal
products, including spinal stimulation devices, spinal hardware and
orthobiologics; and other products, such as arthroscopy products and
softgoods and bracing products. Headquartered in Warsaw, Indiana,
Biomet and its subsidiaries currently distribute products in more than
100 countries.
For further information contact Greg W. Sasso, Senior Vice
President, Corporate Development and Communications at (574) 372-1528
or Barbara Goslee, Manager, Corporate Communications at (574)
372-1514.
This press release contains certain statements that are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934, as amended, such as the Company's estimated results. Although
the Company believes that the assumptions, on which the
forward-looking statements contained herein are based, are reasonable,
any of those assumptions could prove to be inaccurate given the
inherent uncertainties as to the occurrence or non-occurrence of
future events. In particular, the Company cautions the reader that the
results discussed herein are only estimates, and that new or
additional information could cause such results to differ materially.
There can be no assurance that the forward-looking statements
contained in this press release will prove to be accurate. Some of the
factors that could cause actual results to differ from those contained
in forward-looking statements made in this press release include the
success of the Company's principal product lines, the Company's
ability to develop and market new products and technologies in a
timely manner, government regulation, currency exchange rate
fluctuations, reimbursements from third party payors, litigation,
revenue and earnings estimates, and other risk factors as set forth
from time to time in the Company's filings with the SEC. The inclusion
of a forward-looking statement herein should not be regarded as a
representation by the Company that the Company's objectives will be
achieved. The Company undertakes no obligation to publicly update
forward-looking statements, whether as a result of new information,
future events or otherwise.
All of Biomet's financial information may be obtained on our
website at www.biomet.com or you may contact us by e-mail at
investor.relations@biometmail.com.